Latest study leverages new constructs for nuclear localization signal (NLS) sequences to improve editing efficiency in human immune cells.

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $37.77, representing a -0.03% change from its previous close.

The CRISPR gene editing technology has revolutionized the field of molecular biology, offering unprecedented precision and efficiency in genetic manipulation. With its vast potential in various ...

The North America CRISPR gene editing market is poised for substantial growth, with projections indicating a robust annual expansion of 24.4% throughout the forecast period. By 2031, it is anticipated ...

BofA lowered the firm’s price target on Crispr Therapeutics (CRSP) to $80 from $86 and keeps a Buy rating on the shares. While Q1 earnings ...

The prospects for a one-time treatment that reduces the risk of heart disease for the rest of a person’s life just got ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics (NasdaqGM:CRSP) witnessed a notable 25% gain over the past week, gaining traction amid an executive departure. The announcement of COO Julianne Bruno’s exit could have influenced ...

As the demand for precision and efficiency in genetic research continues to grow, Creative Biogene's CRISPR library screening service stands out, allowing scientists to quickly identify and analyze ...

Learn about Brink Therapeutics as it raises $4 million to go beyond CRISPR with engineered recombinases in CAR T therapy.

The Food and Drug Administration has approved the world’s first medicine based on CRISPR gene-editing technology, a ...

The global gene therapy market is projected to grow at a significant CAGR of 20% from 2024 to 2029. This growth is driven by ...